About
Antibody Therapeutics
Areas of Focus
Categories
Biologics & BiopharmaceuticalAntibodyBiotech
Clinical Trials (4)
View allTotal Trials
4
As Lead Sponsor
4
As Collaborator
0
Total Enrollment
167
By Phase
PHASE2: 2PHASE1: 2
By Status
COMPLETED: 2RECRUITING: 1TERMINATED: 1
Clinical Trials Pipeline4 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
Today
Hover over trial bars to see details
Recent Trials
NCT06109441Lead Sponsor
Efficacy/Safety of ALTB-268 in Subjects w/Moderately to Severely Active UC Refractory to Biologics
PHASE2Recruiting
50 participants
Started: Dec 4, 2023 · Completed: Nov 30, 2026
NCT05723692Lead Sponsor
A First-In-Human SAD and MAD Study to Evaluate the Safety, Tolerability, PK and PD of SC Administered ALTB-268 in Healthy Volunteers
PHASE1Completed
56 participants
Started: Jan 17, 2023 · Completed: Oct 27, 2023
NCT03327857Lead Sponsor
Neihulizumab (ALTB-168) in Patients With Steroid-refractory Acute Graft-versus-host Disease or Treatment-refractory Acute Graft-versus-host Disease
PHASE1Completed
37 participants
Started: May 31, 2018 · Completed: Dec 31, 2022
NCT03298022Lead Sponsor
Efficacy&Safety of ALTB-168 in Patients With Moderate to Severe Active,Anti-TNF Alpha and/or Anti-integrin Refractory UC
PHASE2Terminated
24 participants
Started: May 4, 2018 · Completed: Jun 1, 2020
Locations (1)
Headquarters
San Francisco, CA, United States
Map
Loading map...